Windtree Therapeutics, Inc. (NASDAQ:WINT) Files An 8-K Regulation FD Disclosure

Windtree Therapeutics, Inc. (NASDAQ:WINT) Files An 8-K Regulation FD Disclosure
Item 7.01

Story continues below

On November 16, 2020, the Company released an investor presentation to be used in presentations to investors from time to time. A copy of this investor presentation is attached hereto as Exhibit 99.2. 

The information contained in each of Item 2.02 (including Exhibit 99.1) and Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.2 Windtree Therapeutics, Inc. Investor Presentation
 
 

WINDTREE THERAPEUTICS INC /DE/ Exhibit
EX-99.1 2 ex_214273.htm EXHIBIT 99.1 ex_214273.htm Exhibit 99.1       Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates      WARRINGTON,…
To view the full exhibit click here

About Windtree Therapeutics, Inc. (NASDAQ:WINT)

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

An ad to help with our costs